Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
abnormal, abridge, Absent, accuracy, actuarial, Adaptive, addiction, addictive, Additionally, administered, advantage, advice, Agenda, andZocor, antibacterial, antibiotic, antiviral, array, Asia, assumption, attempting, attestation, automatically, AVELOX, avoid, Baxter, Bayer, BBB, Beecham, begun, bioequivalence, Biopharma, border, Centocor, CEO, Chamber, Chemical, chemistry, China, CIA, CIPRO, collusion, complex, confirmed, congestion, conjunction, consecutive, constructive, convert, convertible, core, COSO, counter, cream, creating, Creation, Creelman, criteria, critical, cumulative, decade, declared, deficiency, delivery, Delta, dermatological, desist, detected, detection, deteriorate, deterring, dialogue, diminish, diminished, disincentive, docket, dysfunction, Eisai, erectile, error, exploring, expressed, FIFO, finite, Framework, Frameworkissued, Fred, FREEZE, garenoxacin, GlaxoSmithKline, grace, growing, guilty, Ian, IBM, illicit, imposing, improper, inadequate, incident, incidental, incremental, indefinite, indefinitely, INEGY, infrastructure, ingredient, inInternal, integral, Integrated, integrity, intermediate, Investor, involuntary, iv, Kaposi, Kingdom, Kohan, Korea, Labor, leadership, Leder, LEVITRA, LIFO, Likewise, MA, mandatory, margin, matching, Medipha, methamphetamine, MHLW, Millennium, minimized, Ministry, monitoring, multiplied, NJ, NOL, obligor, opiate, opportunity, OraSure, ordinary, outsource, ovarian, overhead, override, overriding, Overview, personnel, pertain, Pfizer, pharmacist, Philip, physical, PLC, pled, plough, pocket, predominantly, processing, prudent, PSE, pseudoephedrine, psoriatic, published, quinolone, Rabbi, Reclassification, recruited, regular, reiterated, reliance, renewable, reorganized, repaid, repair, repairing, repurchased, reverting, robust, rollover, Rome, Sabatino, Sante, sarcoma, screening, SERP, shelf, shutdown, situation, Smith, SmithKline, source, spoilage, Squibb, statin, steroid, strain, strained, strategic, strong, study, sublicense, subordinated, subsidized, suffered, Summit, suncare, supervision, surveillance, technical, TEQUIN, Toyama, track, trademark, Transformational, Treadway, unauthorized, underlying, underwriting, unissued, unqualified, unremitted, unvested, upfront, upgrade, upper, Upsher, usage, vast, version, vision, volatile, vulnerable, VYTORIN, Watch, website, William, withholding, WTO
Removed:
Accountability, albuterol, Alpharma, andrx, arbitration, Argentina, BAIN, BANAMINE, Barceloneta, barring, Belgium, Biogen, Boehringer, CEDAX, CELESTAMINE, CELESTONE, CEPRAVIN, Circuit, claiming, CLEAR, Cleveland, cold, connecting, conspiracy, constitute, Copley, COPPERTONE, Cosmetic, decongestant, deeply, Diego, DIPROLENE, DIPROSONE, DIPROSPAN, discrimination, distributor, Donald, EULEXIN, falsely, GARAMYCIN, gene, Geneva, Genpharm, Goldline, hearing, Impax, implant, indeterminate, infringe, Ingelheim, issuing, LOTRISONE, maximize, McNeil, merit, Miami, Miller, Mylan, Novex, NUFLOR, nutritional, Occasionally, Omaha, operator, opted, otic, OTOMAX, outpatient, owner, PAC, pediatric, Pharma, plant, POLARAMINE, policy, Porcine, Portability, PRIME, promotant, PROVENTIL, QUADRIDERM, RALGRO, Ranbaxy, REBETRON, recharacterization, refusing, Reproductive, responding, restrain, retailer, retain, reversal, royalty, San, Singapore, SOLARCAINE, SOLEIL, solution, Spain, stating, submission, submitted, sued, sulfate, supplied, syrup, Taro, Technology, Tennessee, Teva, thereof, USA, USPD, vaccine, VALISONE, verdict, Vetmedica, vicinity, violated, violation, Wyeth, Zenith
Filing tables
Filing exhibits
- 10-K Annual report
- 10 EX-10.E.VI: Revised Form of Employment Agreement
- 10 EX-10.E.XI: Severence Benefit Plan As Amended and Restated
- 10 EX-10.L: Retirement Benefits Equalization Plan
- 10 EX-10.N: Cash Long-term Incentive Plan
- 10 EX-10.O: Long-term Performance Share Unit Incentive Plan
- 10 EX-10.W Summary of Director Compensation
- 12 EX-12: Computation of Ratio of Earnings to Fixed Charges
- 21 EX-21: Subsidiaries
- 23 EX-23: Consent of Deloitte & Touche LLP
- 24 EX-24: Power of Attorney
- 31.1 EX-31.1: Certification
- 31.2 EX-31.2: Certification
- 32.1 EX-32.1: Certification
- 32.2 EX-32.2: Certification
Related press release
MRK similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION
I, Fred Hassan, Chairman of the Board, Chief Executive Officer and President of Schering-Plough Corporation, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Annual Report on Form 10-K for the year ended December 31, 2004 (the “Annual Report”) which this statement accompanies fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of Schering-Plough Corporation.
Dated: March 8, 2005
/s/ Fred Hassan
Fred Hassan
Chairman of the Board,
Chief Executive Officer
and President
Chairman of the Board,
Chief Executive Officer
and President